b cell lymphoma symtomas | Aggressive B-cell lymphomas Aggressıve B CELL LYMPHOMAS

Aggressive B-cell lymphomas
Aggressıve B CELL LYMPHOMAS



Summary
The WHO classification is aggressive B-cell lymphomas, Difuz large B cell lymphoma (DBBL), Burkitt lymphoma/leukemia, and precursor B lymphoblastic leukemia/lymphomas. These show itself as nodal or extranodal and localized or disseminated. DBBL is the most common type of non-Hodgkin lymphoma and constitutes 30% of cases. It is usually welded in de novo (primer) but is the progression/transformation of less aggressive lymphomas such as chronic lymphocytic leukemia/small lymphocytic lymphoma, follicular lymphoma, marginal zone lymphoma, and rich Hodgkin lymphoma of Nodular lymphocyte ( Secondary). Various morphological and subtypes of DBBL are defined in the WHO classification. Burkitt lymphoma/leukemia is an aggressive tumor that shows the proliferation of middle-size B cells resulting in disregulation of C-Myc Oncogen. There are clinical subgroups associated with endemic, sporadic and immunodeficiency. Morphological properties of some tumors are between Burkitt lymphoma and DBBL. These are referred to as the subtype of Burkitt lymphoma in the WHO classification and are named as Burkitt-like lymphoma/atypical Burkitt. Precursor b lymphoblastic leukemia (ALL)/lymphoma (BLL) is composed of precursor B cells called Lymphoblast. Leukemia and lymphoma contain clinical, pathological, immunological, cytogenetic properties that overlap with each other. Therefore, it is regarded as a different clinical presentation of the same antimatter. BBL is the rarest type of lymphomas.

Keywords: difuz large B cell lymphoma, WHO classification, Burkitt lymphoma, precursor b lymphoblastic leukemia/lymphoma

ABSTRACT

The World Health Organization (WHO) classification, aggressive B cell lymphomas are diffuse Large B cell Lymphoma (DLBL), Burkitt Lymphoma/leukemia and precursor lymphoblastic leukemia/Lymphoma. They may present either nodal or extranodal disease, which maybe either localized or disseminated. DLBL is most common type of non-Hodgkin's lymphoma, account for about 30% of the cases. They usually arise from de novo (primary) but can represent progression/transformation (secondary) of a less aggressive lymphoma; e.g. chronic lymphocyctic leukemia/small lymphocytic lymphoma, follicular lymphoma, marginal zone B cell lymphoma and Nodus lymphocyte predominant Hodgkin lymphoma. In the WHO classification several morphologic variants and subtypes of DLBL are described. More recently, Gene expression profile has been examined by Microarray technology has identified two main groups of DLBL: Germinal Center-like dlbl and post-tensional center-like (activated B-cell) dlbl. Besides the different biological behavior, these groups show differences in terms of clinical features and outcome. Burkitt lymphoma is a highly aggressive tumour of medium-sized, proliferating B cells, typically with translocations in deregulation of the C-Myc oncogene. Clinical subtypes include endemic, sporadic and immunodeficiency-associated. Some tumours that have morphologic features intermediate between typical Burkitt lymphoma and dbbl. In the WHO classification, this category is considered a subtype of Burkitt lymphoma: so-called Burkitt-like lymphoma/atypical Burkitt. Precursor b lymphoblastic leukemia (ALL)/lymphoma (BLL) are derived from Precursor B called cells lymphoblast. BLL and ALL share overlap clinical, pathologic, Immunologic, cytogenetic features. For this reason, BLL and ALL represent different manifestations of the same disease. BLL is uncommon type of non-Hodgkin's Lymphomas.

Keywords: Diffuse large cell lymphoma, WHO classification, Burkitt lymphoma, precursor B lymphoblastic leukemia/lymphoma